TREMFYA®: A Giant Step for Psoriatic Arthritis!

Johnson & Johnson announced groundbreaking new data in the treatment of Psoriatic Arthritis (PsA). TREMFYA® significantly prevented the progression of structural damage at week 24 and maintained this effect until week 48. These findings were presented at the Inflammatory Skin Diseases Summit (ISDS).

In the Phase 3b APEX study conducted, over 50% of patients receiving TREMFYA® achieved a 50% improvement in PsA symptoms by week 48. At week 24, patients treated with TREMFYA® were able to prevent structural damage in the joints 2.5 times more effectively than the placebo group.

Patients in the placebo group, upon switching to TREMFYA® at week 24, observed a 57% reduction in the rate of exacerbation. Dr. Christopher Ritchlin emphasized that PsA is a rapidly progressive disease if left untreated, highlighting that guselkumab can prevent this progression.

TREMFYA® showed significant improvement in response criteria according to the American College of Rheumatology (ACR50). Both the groups receiving doses every 4 weeks and those every 8 weeks showed an increase in ACR50 response rates. These data are consistent with the well-known safety profile of TREMFYA®.

Leonard Dragone stated that TREMFYA® is the only IL-23 inhibitor that can prevent structural damage in active PsA. This treatment option offers an attractive first-line therapy for patients with psoriatic diseases.

TREMFYA® is a fully human monoclonal antibody that blocks IL-23 and neutralizes inflammation at its cellular source by binding to CD64 present on the surface of IL-23 producing cells. Johnson & Johnson also submitted additional data to the FDA for a supplementary Biologic License Application to prevent structural damage in patients with active PsA.